World ADC on October 12-15, 2026 in San Diego, United States

With groundbreaking clinical impact of traditional ADCs in first-line metastatic indications and ambitions set on neoadjuvant settings, the new era of ADCs are starting to enter the clinic and attract dealmaking attention, unlocking the next wave of differentiated ADCs to redefine the future standard of care in oncology and beyond.

Returning as the largest and definitive ADC congress, the 17th World ADC San Diego is THE one-stop bioconjugate shop bringing together the global ADC community for an unparalleled amalgamation of case studies, development trends and networking opportunities to forge ADC innovation into differentiated, early-line patient outcomes.

With 7 streams of end-to-end ADC content across Discovery Chemistry, Discovery Biology, Preclinical, Translational Medicine, Clinical Lessons, Process and Analytical Development, and Manufacturing and Supply Stream, all the ADC innovation will be in the spotlight for an unmissable week of data and insights to de-risk future ADC development and push ADCs into earlier-line oncology treatments.

Uniting 1,300 industry senior enthusiasts from biopharma, innovative start-ups, leading service providers and academic, physician and regulator KOLs, World ADC San Diego is the place to be to discuss, debate and advance the future of ADC development.

URLs:
Tickets: https://go.evvnt.com/3631918-2?pid=10008
Brochure: https://go.evvnt.com/3631918-3?pid=10008

Time: 8:00 AM - 6:00 PM

Venue Details: Town and Country Resort, 500 Hotel Circle North, San Diego, California, 92108, United States

Category: Conferences | Science, Health and Medicine

Prices:

Conference + Seminar Day - Primary: USD 4248.00,

Conference + Workshop Day: USD 4248.00,

Conference + Seminar Day and Workshop Day - Primary: USD 5297.00,

Conference + Seminar Day - Academic: USD 3697.00,

Conference + Workshop Day - Academic: USD 3697.00,

Conference + Seminar Day and Workshop Day: USD 4695.00,

Conference + Seminar Day - Vendor: USD 6297.00,

Conference + Workshop Day - Vendor: USD 6297.00,

Conference + Seminar Day and Workshop Day - Vendor: USD 7659.00

Speakers: Jack Chen, Scientific Director - Translational Oncology, Precision Medicine, Abbvie, Petra Dieterich, Senior Vice President and Scientific Leader, Abzena, Tomohiro Fujii, Senior Researcher, Ajinomoto Bio-Pharma Services, Sonia Appel, Founder and Principal Consultant, Alismere, Suzanne Edavettal, Vice President, Research and Head, Protein Therapeutics, Amgen, Herbert Ogutu, Senior Manager, Contract and Development Manufacturing, Amgen, Vinod Bulusu, Executive Director, Product Stewardship Lead, AstraZeneca, Alyn Davies, Associate Director, Medicinal Chemistry, AstraZeneca, Malini Iyer, Associate Director, Oncology Safety and Discovery, AstraZeneca, Seb Caille, Senior Director, AOC Process Development, Avidity Biosciences, a Novartis Company, Raj Kumar, Commercial Partner, Beacon by Hanson Wade, Sarah Shi, Director, Regulatory CMC, BeOne Medicines, Steve Walsh, Principal Scientist, Project Leader, Bicycle Therapeutics plc, L. Nathan Tumey, Associate Professor, Binghampton University, Jian Chen, Director - Translational Research and Preclinical Development, BioAtla, Rakesh Dixit, President and Chief Executive Officer, Bionavigen Oncology, David Bramhill, President and Founder, Bramhill Biologics Consulting, Giorgia Vicentini, Vice President, Program Lead, Oncology, Bristol Myers Squibb, Hui Wei, Chair, Biologics Specification Committee and Head, Biologics Analytical Technical Integration, Bristol Myers Squibb, Wim Dokter, Chief Scientific Officer, Byondis B.V., Jerome Boyd-Kirkup, Chief Scientific Officer, Callio Therapeutics, Henry Yu, Chief Executive Officer, CanWell Pharma Inc, Sean Muthian, Vice President, Chief Technology and Strategy Officer, Cytiva, Sean McCarthy, Chief Executive Officer, CytomX Therapeutics, Kohei Takano, Scientist, Discovery Research, Daiichi Sankyo, Ronald Fleming, Executive Director, Clinical Development, Daiichi Sankyo, Sophia Xu, Director, Clinical Bioanalysis, Daiichi Sankyo,, Dae-Shik Kim, Sr Principal Scientist, Eisai Co., Ltd., Jonathan Harris, Executive Director, Regulatory Affairs CMC, Exelixis, Pooja Desai, Director - Biotherapeutics and Chemistry, Manufacturing, and Controls Team Lead, Exelixis, Inc., Hui Zhao, Senior Director, Translational Biology, Exelixis, Inc., Bingchuan Wei, Senior Principal Scientist, CMC Team Lead, Genentech, Gail Lewis, Distinguished Scientist, Discovery Oncology, Genentech, Melissa Schutten, Executive Director, Nonclinical Sciences and Pathology, Gilead Sciences , Matt Lorenz, Director, Bio Pivotal Analytical Development, Gilead Sciences, Nathan Ihle, Founder and Principal Ihle ,CMC Solutions, Jutta Deckert, Vice President - Research and Development, Iksuda Therapeutics, Bob Lutz, Chief Scientific Officer, Iksuda Therapeutics, Min Hu, Senior Vice President, Discovery, Innovent Biologics, Mohit Trikha, Chief Executive Officer, Kivu Biosciences, Aaron Pruett, Principal Scientist - Drug Product Sciences, MacroGenics, Paritosh Pande, Associate Principal Scientist, Sterile Drug Product Commercialization, Merck and Co., Patrick Zweidler-McKay, Chief Medical Officer, NEOK Bio, Ya-Chi, Chen Chief Scientific Officer, OBI Pharma, David Huang, Senior Director, ADC Enabling Technologies, OBI Pharma, Inc., Christian Rohlff, CEO Oxford, BioTherapeutics Ltd, Scott Peterson, Head of ADC Discovery, Pfizer, Jeffrey Settleman, Chief Scientific Officer, Oncology R and D, Pfizer, Sujata Narayanan, Vice President, Global Development Product Lead, Pfizer, John Lambert, Independent Consultant and Honorary Professor, Queens University Belfast, Wenhua Wang, Fellow Scientist, Regeneron, Sunnie Kim, Associate Director, Analytical Sciences, Regeneron Pharmaceuticals, Sanjeevani Ghone, Founder and Consultant, SACHEMIE Consultancy, Samuel Murphy, CEO Salubris, Biotherapeutics Inc., Ruby Casareno, Biologics CMC Consultant, Self-Employed, Ruby Casareno, Biologics CMC Consultant, Self-Employed, Hanspeter Gerber, Chief Scientific Officer, Sutro Biopharma, Alice Yam, Vice President, Early Development and Strategic Program Management, Sutro Biopharma, Olga Paley, PhD Director and Head of Downstream Process Development Late and Bioconjugation, Takeda, Kai Ni, Staff Engineer, Takeda Pharmaceutical, Dominik Schumacher, Chief Executive Officer, Tubulis, Rita Nanda, Associate Professor, Medicine and Director, Breast Oncology, Section of Hematology/ Oncology, University of Chicago, Greg Thurber, Professor of Chemical and Biomedical Engineering, University of Michigan, Thomas Rohrer, Vice President, Bioconjugation, Veranova, Marie Zhu, Chief Technology Officer, WuXi XDC